Next Article in Journal
Exploring the Potential of Extracts from Sloanea medusula and S. calva: Formulating Two Skincare Gels with Antioxidant, Sun Protective Factor, and Anti-Candida albicans Activities
Previous Article in Journal
Neuroprotective Effects of Albizia lebbeck (L.) Benth. Leaf Extract against Glutamate-Induced Endoplasmic Reticulum Stress and Apoptosis in Human Microglial Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 16
Issue 7
10.3390/ph16070988
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Effects of Perilla frutescens Extracts on IgA Nephropathy: A Systematic Review and Meta-Analysis

by
Gigi Adam
1,2,†,
Ana-Maria Adam
3,*,
Silvia Robu
3,†,
Valeriu Harabor
3,
Anamaria Harabor
3,
Aurel Nechita
3,
Denisa Batir Marin
1,
Ionela-Daniela Morariu
1,
Oana Cioanca
1,*,
Ingrid-Andrada Vasilache
4 and
Monica Hancianu
1
1
Faculty of Pharmacy, “Grigore T. Popa” University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania
2
Department of Pharmaceutical Sciences, Faculty of Medicine and Pharmacy, ‘Dunarea de Jos’ University, 800216 Galati, Romania
3
Clinical and Surgical Department, Faculty of Medicine and Pharmacy, ‘Dunarea de Jos’ University, 800216 Galati, Romania
4
Department of Obstetrics and Gynecology, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceuticals 2023, 16(7), 988; https://doi.org/10.3390/ph16070988
Submission received: 11 June 2023 / Revised: 4 July 2023 / Accepted: 5 July 2023 / Published: 10 July 2023
(This article belongs to the Section Natural Products)
Browse Figures
Versions Notes

Abstract

:
(1) Background: Chronic renal disorders (CRD) are associated with significant comorbidities and necessitate complex therapeutic management. As time passed, Perilla frutescens (PF) became a promising therapeutic option for CRD. The aim of this systematic review and meta-analysis was to outline the therapeutic effects of PF extracts on various models of immunoglobulin a (IgA) nephropathy; (2) Methods: Medline, Embase, and Cochrane databases were used to find relevant studies. All prospective interventional studies that evaluated the effect of PF extract versus placebo on rat models of chronic renal disorders were assessed according to the international guidelines; (3) Results: Our search yielded 23 unique records, out of which only five were included in the analysis. Our results showed that administration of PF extracts led to a statistically significant reduction in proteinuria and PCNA levels in rats that received high doses of the extract as well as in the PCNA level and DNA synthesis in rats that received low doses of the extract. The evaluated outcomes benefited from a low degree of heterogeneity; (4) Conclusions: Some of the evaluated outcomes were significantly reduced by both high and low doses of extracts from Perilla frutescens. Further studies are needed to determine the exact effect over IgA nephropathy in human subjects.

1. Introduction

Chronic kidney disease (CKD) is a major public health problem that can drain significant financial and social resources. Furthermore, it is a risk factor for hypertension and cardiovascular disease, both of which are significant causes of morbidity and mortality in the general population of most countries [1,2]. The global prevalence of CKD (stages 1–5) is estimated to be 3–18%, with a greater prevalence in females than males, at least among those aged >40 years at the time of CKD diagnosis, and a significant contribution from the geriatric population [3,4,5,6]. According to a systematic analysis by Mills et al., the age-standardized prevalence of CKD stages 1–5 among individuals living in 32 countries was 10.4% among men and 11.8% among women (range 4.5–25.7% for men and 4.1–18.4% for women) [7].
Renal disorders comprise a diversity of pathological entities aside from CKD, including nephropathies, glomerulopathies, acute kidney injury, autoimmune disorders, and tumors [8]. Mesangioproliferative glomerulonephritis (MesPGN) is a distinct glomerular response pattern characterized by a diffuse or focal increase in the number of mesangial cells and expansion of the extracellular matrix in the glomerular mesangium, with or without immunoglobulin or complement deposition [9]. This pattern can be encountered in several groups of renal diseases including IgA nephropathy (IgAN), IgM nephropathy (IgMN), lupus nephritis (LN), C1q nephropathy (C1qN), and other entities [10,11,12].
IgAN is the most frequent type of primary glomerulonephritis and one of the leading causes of renal failure [13]. The prevalence of IgAN differs significantly depending on racial background, with East Asians having the highest incidence, followed by Caucasians [14]. Its incidence has been estimated to be 2–10 per 100,000 person-years, with peaks occurring throughout the second and third decades of life [15].
The diagnosis of IgAN is primarily conducted using histopathological examination of renal biopsies, and the current treatment involves maintaining appropriate blood pressure control with an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) medication, corticosteroid therapy, immunosuppression, and ultimately kidney transplant [16]. The individualized management of these disorders is often difficult due to their great complexity, and numerous herbal extracts have been investigated as potential therapeutic means [17,18,19,20].
Perilla frutescens (L.) Britt., a member of the Labiatae family, is widely spread around the world, particularly in Eastern Asian countries [21,22]. Flavonoids, volatile oils, fatty acids, triterpenes, phenolic compounds, and other substances have been extracted and identified from this plant [22]. Moreover, a recent review highlighted substantial therapeutic properties of this herb, including antioxidant, antibacterial, anti-allergic, antidepressant, anti-inflammatory, antitumoral, and neuroprotection actions [23].
Although these effects resulted from the analysis of in vitro and in vivo studies, there were few clinical trials that outlined significant therapeutic effects for human subjects. Attenuation of age-related cognitive decline, antiallergic, antioxidant, prokinetic, and antispasmodic effects are among the proven therapeutic proprieties of Perilla frutescens in these studies [24,25,26,27,28,29].
A recent literature review outlined the main applications of Perilla frutescens in clinical practice using data derived from human studies and indicated that the extracts from this herb have demonstrated anti-inflammatory, antiallergic, antioxidant, and hypolipemiant effects in humans [30]. Other miscellaneous effects referred to its antibacterial and antifungal proprieties as well as its role as a prebiotic and reliever of gastrointestinal discomfort.
MesPGN is a renal disorder with an important inflammatory component, and it constitutes an interesting target for possible therapeutic approaches based on Perilla frutescens extracts. The effects of Perilla frutescens extracts are poorly studied in the literature, and the aim of this systematic review and meta-analysis is to outline their therapeutic effects on IgA nephropathy.

2. Results

Our search yielded 23 unique records, out of which only five were included in our systematic review after abstract and full text screening (Figure 1). We did not retrieve additional items after screening references and related articles.
The characteristics of the included studies are presented in Table 1. A total of 158 rat models and five studies [22,23,24,25,26] were included in the meta-analysis, while other studies were excluded mainly because the statistical analyses were not informative when using insufficient data. For the purpose of this meta-analysis, we evaluated the therapeutic effects of Perilla frutescens on animal models that were mentioned at least twice.
The quality of the included studies was assessed using SYRCLE’s risk of bias tool for animal studies (Table 2). Only one study randomly allocated animal models to the intervention and control groups [35]. It is unclear if the other studies randomly allocated animal subjects to a specific intervention. All studies evaluated similar animal models, but the risk was unclear regarding the concealment of different group segregations by investigators.
The housing of these animals was not extensively described in all evaluated studies; thus, the lack of details resulted in an unclear risk of bias assessment regarding this domain. No study found a high risk of bias in one domain (subject selection). The investigators were not blinded from knowledge of which intervention each animal received during the experiment in all studies performed by Makino et colleagues, while this aspect was unclear for the study performed by Sakurai et al. [35]. These aspects suggest a possible performance bias of the evaluated studies.
None of the studies indicated that the animals were selected at random for outcome assessment, and it remains unclear if the outcome assessor was blinded, thus suggesting a possible risk of detection bias.
All studies adequately addressed incomplete outcome data, and the reports of the studies were free of selective outcome reporting, thus resulting in a lack of attrition or reporting bias. No other biases were identified while using the SYRCLE’s risk of bias tool. No studies were excluded from the analysis based on their quality.
The results of the random effects model used for meta-analysis are presented in Table 3, and the forest plots are depicted in Figure 2, Figure 3, Figure 4, Figure 5, Figure 6, Figure 7 and Figure 8. Administration of Perilla frutescens extracts determined a statistically significant reduction in the proteinuria level in rats that received high doses of the herb (p < 0.001), in the PCNA level for both groups versus placebo (p < 0.001), as well as in the [3H] thymidine incorporation as a measure of DNA synthesis for the low-dose group (p < 0.001). On the other hand, we could determine a great deal of heterogeneity between studies, ranging from 88–100% for the majority of the reported outcomes. A low to medium heterogeneity (I2: 0–53%) was observed for studies reporting the following outcomes: proteinuria for the high-dose versus placebo groups, and PCNA or DNA synthesis for the low-dose versus placebo groups.
The funnel plot of the pooled treatment effects estimated from individual studies against a measure of study size is presented in Figure 9. Its shape is slightly asymmetrical, indicating a possible publication bias, and there are small studies of inadequate quality whose results are biased towards larger beneficial effects.

3. Discussion

This systematic review and meta-analysis evaluated the therapeutic effects of Perilla frutescens on various animal models of IgA nephropathy. Our results showed that administration of Perilla frutescens extracts led to a statistically significant reduction in proteinuria and PCNA levels in rats that received high doses of the extract as well as in the PCNA level and DNA synthesis in rats that received low doses of the extract. The evaluated outcomes benefited from a low degree of heterogeneity.
Proteinuria was identified as the most widely recognized and well-studied risk factor for progression to end-stage chronic renal disease in IgAN [36]. It can be used as a basis for accelerated approval of therapies intended to treat serious or life-threatening conditions, such as IgAN.
Numerous observational studies have established the significance of both the extent and duration of proteinuria in relation to the progression of IgAN [36,37,38]. The degree of advancement is notably slower in individuals who excrete less than 1 g/day, while it is most pronounced in those who excrete more than 3 to 3.5 g/day.
In a study that evaluated 542 adult patients diagnosed with IgAN over a period of 6.5 years, it was found that the rate of decline in kidney function was significantly higher in patients with consistent proteinuria levels exceeding 3 g/day compared to those with protein excretion levels below 1 g/day [39]. The former group experienced a decline of 0.72 mL/min/1.73 m2 per month, which was 24 times faster than the latter group’s decline rate of 0.04 mL/min/1.73 m2 per month. This study highlighted the negative impact of sustained proteinuria on kidney function in patients with IgAN.
Patients exhibiting proteinuria levels exceeding 3 g/day who achieved partial remission (less than 1 g/day) demonstrated a comparable rate of progression to renal failure as those who sustained proteinuria levels below 1 g/day from the time of presentation [39]. The correlation between elevated proteinuria levels and a poorer prognosis can be attributed, at least partially, to proteinuria serving as an indicator of the gravity of the glomerular ailment.
Several studies indicate that nearly one-third of patients exhibiting high-risk histologic features, particularly those with notable hematuria, display proteinuria levels below 1 g/day and subsequently encounter a decline in kidney function [40]. The presence of proteinuria below 1 g/day as an isolated clinical finding cannot ensure a favorable prognosis or imply the absence of a necessity for intervention.
[H3] thymidine incorporation was used in multiple rat models and human cell lines as an indirect marker of DNA synthesis and cell proliferation [41,42,43,44]. Thus, a reduction in [H3] thymidine incorporation translates into a reduction in cell proliferation, in our case of mesangial proliferation.
Recent research has produced a four-hit concept for the development and/or clinical manifestations of IgA nephropathy [45]. Galactose shortage of some O-linked glycans in the hinge region of IgA1 initiates a chain of events that may result in renal damage. IgA1 galactose-deficient O-glycans are made up of terminal N-acetylgalactosamine (GalNAc) or sialylated GalNAc [46,47]. Anti-glycan antibodies identify the hinge-region glycans of IgA1 with terminal Gal-NAc [46,48], resulting in the formation of nephrotoxic circulating immune complexes that deposit in the glomerular mesangium, causing kidney damage [46]. Numerous literature reviews have outlined the association between high serum IgA levels and IgAN severity and activity [49,50].
Proliferating cell nuclear antigen (PCNA) is an acidic nuclear protein that increases from the late G1 to S phases of the cell cycle and whose detection parallels other standard methods for assessing cell proliferation [51,52]. Nakopoulou et al. investigated the PCNA expression in normal and diseased human kidneys and defined a possible correlation of its expression with various types of glomerulonephritis (GN) [53]. The authors demonstrated a significantly higher expression on the histopathological probes from subjects with IgA nephropathy.
While clinical features have been identified as robust prognostic indicators, specific histological markers identified during kidney biopsy in IgAN patients have been linked to an elevated risk of disease progression. These markers comprise both indicators of marked inflammatory disease, such as crescent formation and immune deposits in the capillary loops, alongside the mesangial deposits that are universally present in all patients [54,55]. Additionally, they encompass markers of persistent fibrotic disease, such as glomerulosclerosis, tubular atrophy, interstitial fibrosis, and vascular disease, as documented in various sources [56,57,58]. The incorporation of contemporary pathological discoveries enhances the precision of prognostication beyond the exclusive consideration of clinical characteristics upon evaluation during the kidney biopsy.
The utilization of the revised Oxford classification of IgAN involves the evaluation of kidney biopsies through the assessment of five histologic variables, namely mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental glomerulosclerosis (S), tubular atrophy/interstitial fibrosis (T), and crescents (C) [59].
Empirical evidence has demonstrated that each of the aforementioned variables possesses the ability to predict kidney outcome in isolation, irrespective of clinical data. Moreover, a recent international multiethnic cohort study on 3927 patients evaluated the predictive performance of a model that comprised clinical and histological risk factors for the prediction of the risk of a 50% decline in kidney function or end-stage renal disease in patients with IgA nephropathy [60]. The model was internally and externally validated, obtaining good predictive results. As such, the influence of novel therapeutic agents over these markers could be assessed in clinical trials that could potentially establish various correlations between treatment effects and degree of positivity as well as with clinical outcomes.
Perilla frutescens contains a high amount of n–3 polyunsaturated fatty acids (PUFA) that have been proven to modulate immune and inflammatory responses [61,62]. PUFA has been observed to exert beneficial effects on various stages of renal fibrosis, including mesangial cell activation and proliferation as well as extracellular matrix protein synthesis. These effects are mediated through the regulation of pro-inflammatory cytokine production, renin and nitric oxide (NO) systems, and the expression of peroxisome proliferator-activated receptor genes [63]. As we previously outlined, IgA nephropathy is a kidney disorder with an important inflammatory component; thus, we hypothesize that Perilla frutescens extracts could potentially have an impact on this disease progression. However, there are no studies on human subjects that have analyzed this topic.
These arguments support the hypothesis that the evaluated outcomes were significantly reduced by both high and low doses of extracts from Perilla frutescens. Thus, they could be further evaluated in a clinical trial setting, on a larger cohort of patients, in order to determine the exact effect on chronic renal disorders and their impact on clinical and histological markers of disease progression.
Mesangioproliferative glomerulonephritis has an important inflammatory pathophysiological background that comprises two main elements: deposition of immune complexes or monoclonal immunoglobulins leading to activation of complement, and dysregulation and persistent activation of the alternative complement pathway [64]. On the other hand, the results from in vitro studies indicated that various components of Perilla frutescens extracts, and especially rosmarinic acid, have the potential to reduce vascular permeability and leukocyte migration, cytokine and chemokines secretion, specific antibody production, and nitric oxide production [65,66,67]. Thus, the Perilla frutescens extracts could be considered a viable candidate as an adjuvant therapeutic agent for the modulation of the local inflammatory response characteristic of mesangioproliferative glomerulonephritis.
Researchers should keep in mind that several reports indicated a potential toxicity associated with exposure to Perilla frutescens [68,69], and this aspect is particularly important for those patients with severe forms of IgA in whom the estimated glomerular filtration rate is reduced and who need appropriate dose adjustments to avoid progression to end-stage renal disease and need dialysis.
The toxicity of Perilla frutescens extracts was studied in animal models. It was hypothesized that the most toxic component of this plant is Perilla ketone, which induced pulmonary edema in laboratory animals [70]. Mice and hamsters exhibited relatively low intraperitoneal median lethal dose values (5 mg/kg and 13.7 mg/kg, respectively), whereas dogs and pigs required significantly higher lethal doses (106 mg/kg and 158 mg/kg, respectively) [71]. The predominant manifestation of perilla ketone-associated pathology in dogs and pigs was observed in the liver, with minimal impact on the pulmonary tissue. Conversely, mice and hamsters exhibited solely pulmonary lesions in response to Perilla ketone exposure.
A recent study by Zhang et al. investigated the acute and sub-chronic 90-day oral toxicity of Perilla frutescens seed oil in rodent and dog models [72]. In the acute oral toxicity study, the authors reported no significant treatment-associated toxicity or mortality using Perilla frutescens seed oil dosages of up to 50 g/kg in KM mice and 20 g/kg in Wistar rats; thus, the median lethal dose (LD50) could not be calculated. In the sub-chronic stage, the authors reported soft or mucoid feces along with decreased food consumption in dogs that received high doses of Perilla frutescens seed oil (12 g/kg/day). The urinalysis of these subjects did not reveal any changes in the evaluated parameters (urine occult blood, nitrites, pH, urobilinogen, bilirubin, proteins, glucose, or ketones).
The results from this meta-analysis should be evaluated considering some inherent limitations. First of all, we could not assess all outcomes presented in the studies due to the limited information extracted, which did not allow a coherent statistical analysis. Secondly, we could not include in this study randomized controlled trials because none were conducted until now, and the results are based on interventional studies on animals.
Further studies on larger cohorts of human subjects or several randomized controlled trials could represent scientific material of higher quality for the next meta-analysis. Meanwhile, we consider that our results support some of the favorable outcomes that result from Perilla frutescens administration.

4. Materials and Methods

We performed a systematic search of published studies that evaluated the therapeutic effects of Perilla frutescens extracts on various models of IgA nephropathy in MEDLINE, EMBASE, and Cochrane Library using synonyms of ‘Perilla frutescens’, ‘chronic renal disorder’, ‘nephropathy’, ‘Berger disease’, and ‘glomerulopathy’, and Boolean operators AND/OR, in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Supplementary Material Table S1: PRISMA 2020 checklist).
Additional research consisted of a manual screening of references cited in the evaluated papers in order to ensure that all relevant studies were included. Duplicates were removed using EndNote software version 20.4 (Clarivate, Philadelphia, PA, USA).
This systematic review and meta-analysis is registered in the Open Science Framework (DOI: https://doi.org/10.17605/OSF.IO/MZXYE) and PROSPERO-International prospective register of systematic reviews (ID: CRD42023389256) registries. The time frame settled for this research was from inception up to 31 of December 2022, with an English language restriction.
The inclusion criteria were represented by interventional studies on HIGA and Wistar rats, with a therapeutic study design that compared the therapeutic effects of at least one Perilla frutescens with a control group. We excluded opinion papers, studies that were published in a language other than English, studies in humans or in sillico, and case reports from the search.
The full-text papers were independently reviewed by two investigators (G.A. and A.-M.A.) to establish their eligibility for the review. Any differences between the two were remedied by a third reviewer (M.H.) if a consensus could not be reached. Two investigators (G.A. and V.H.) retrieved data from the eligible studies separately using a standard process. Data concerning the first author, publication year, study design, characteristics of the population examined, number of cases and controls, and therapeutic outcomes were obtained.
The primary outcome evaluated was represented by proteinuria expressed quantitatively (mg/24 ore) or semiquantitatively on a dipstick (proteinuria: − = negative, B = trace; + = 30 mg/dL; ++ = 100 mg/dL, and +++ = 300 mg/mL). The secondary outcomes included the following:
  • Serum IgA levels (mg/dL);
  • Proliferating cell nuclear antigen (PCNA)—the average number of PCNA positive-cells in a glomerular cross section;
  • [3H]Thymidine incorporation (cpm).
Two independent reviewers (I.A.V. and A.H.) assessed the methodological quality of the included studies using SYRCLE’s risk of bias tool [73]. Any disagreements were resolved by discussion with a third reviewer (S.R.). For studies that did not provide sufficient information for a meta-analysis, we chose to present their results in a descriptive manner.
We summarized the data from each study and calculated the standardized mean difference for continuous outcomes. The meta-analysis was performed using a random effects model due to the small cohorts of subjects. In order to show variation and to explore the heterogeneity of the results, we drew forest plots, and we calculated the I2 statistic for a quantification of the degree of heterogeneity. A funnel plot was employed for the evaluation of publication bias among studies. The statistical analyses were performed using STATA SE (version 17, 2021, StataCorp LLC, College Station, TX, USA).

5. Conclusions

This systematic review and meta-analysis indicated that administration of Perilla frutescens extracts led to a statistically significant reduction in proteinuria and PCNA levels in rats that received high doses of the extract as well as in the PCNA level and DNA synthesis in rats that received low doses of the extract.
The pathophysiological background of mesangioproliferative glomerulonephritis is defined by an important local inflammatory response, and Perilla frutescens could potentially modulate this inflammatory response in order to obtain better clinical outcomes.

6. Future Directions of Research

The results of this systematic review and meta-analysis constitute a basis for further clinical trials on animal models and humans that could evaluate the influence of Perilla frutescens extracts administration over the histological markers of progression, clinical evolution, and interaction with other therapeutic agents, as our results benefited from a low degree of heterogeneity.
Since the pattern of mesangioproliferative glomerulonephritis is dynamic and can progress to more severe forms, it is important to identify specific clinical, histological, and molecular targets for various therapeutic agents that would modulate the disease’s evolution and progression to end-stage renal disease.
This study outlined several markers that could potentially be targeted by Perilla frutescens extracts and indicated overall good results. However, it is important to further evaluate the optimal dosage in humans as these extracts have proven to have a certain degree of toxicity.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ph16070988/s1, Table S1: PRSIMA 2020 checklist.

Author Contributions

Conceptualization, G.A., S.R., M.H., O.C. and A.-M.A.; methodology, I.-A.V., V.H., A.H. and A.N.; software, I.-A.V.; validation, D.B.M. and I.-D.M.; formal analysis, I.-A.V., V.H., A.H. and A.N.; investigation, G.A., S.R., M.H., O.C. and A.-M.A.; resources, I.-A.V., V.H., A.H. and A.N.; data curation, D.B.M., and I.-D.M.; writing—original draft preparation, G.A., S.R., M.H., O.C. and A.-M.A.; writing—review and editing, G.A., S.R., M.H., O.C. and A.-M.A.; visualization, I.-A.V.; supervision, M.H.; project administration, G.A.; funding acquisition- none. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

This systematic review and meta-analysis is registered in the Open Science Framework Registry (DOI: https://doi.org/10.17605/OSF.IO/MZXYE), and it is available on: https://archive.org/details/osf-registrations-mzxye-v1 (Accessed on 20 May 2023). This study is also registered in PROSPERO—International prospective register of systematic reviews (ID: CRD42023389256), available on: https://www.crd.york.ac.uk/PROSPERO/#myprospero (accessed on 21 May 2023). Additional data are available upon a reasonable request from the corresponding author due to local policies.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. De Nicola, L.; Zoccali, C. Chronic kidney disease prevalence in the general population: Heterogeneity and concerns. Nephrol. Dial. Transplant. 2016, 31, 331–335. [Google Scholar] [CrossRef] [PubMed]
  2. Ene-Iordache, B.; Perico, N.; Bikbov, B.; Carminati, S.; Remuzzi, A.; Perna, A.; Islam, N.; Bravo, R.F.; Aleckovic-Halilovic, M.; Zou, H.; et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): A cross-sectional study. Lancet Glob. Health 2016, 4, e307–e319. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. De Nicola, L.; Donfrancesco, C.; Minutolo, R.; Lo Noce, C.; Palmieri, L.; De Curtis, A.; Iacoviello, L.; Zoccali, C.; Gesualdo, L.; Conte, G.; et al. Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: Results of the 2008-12 National Health Examination Survey. Nephrol. Dial. Transplant. 2015, 30, 806–814. [Google Scholar] [CrossRef]
  4. Ebert, N.; Jakob, O.; Gaedeke, J.; van der Giet, M.; Kuhlmann, M.K.; Martus, P.; Mielke, N.; Schuchardt, M.; Tölle, M.; Wenning, V.; et al. Prevalence of reduced kidney function and albuminuria in older adults: The Berlin Initiative Study. Nephrol. Dial. Transplant. 2017, 32, 997–1005. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Brück, K.; Stel, V.S.; Gambaro, G.; Hallan, S.; Völzke, H.; Ärnlöv, J.; Kastarinen, M.; Guessous, I.; Vinhas, J.; Stengel, B.; et al. CKD Prevalence Varies across the European General Population. J. Am. Soc. Nephrol. 2016, 27, 2135–2147. [Google Scholar] [CrossRef]
  6. Glassock, R.J.; Warnock, D.G.; Delanaye, P. The global burden of chronic kidney disease: Estimates, variability and pitfalls. Nat. Rev. Nephrol. 2017, 13, 104–114. [Google Scholar] [CrossRef]
  7. Mills, K.T.; Xu, Y.; Zhang, W.; Bundy, J.D.; Chen, C.S.; Kelly, T.N.; Chen, J.; He, J. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int. 2015, 88, 950–957. [Google Scholar] [CrossRef] [Green Version]
  8. Bourey, P.D. Renal disorders. Radiol. Technol. 2008, 79, 433–446; quiz 447–439. [Google Scholar]
  9. Bohle, A.; Wehrmann, M.; Bogenschütz, O.; Batz, C.; Vog, W.; Schmitt, H.; Müller, C.; Müller, G. The Long-Term Prognosis of the of the Primary Glomerulonephritides: A Morphological and Clinical Analysis of 1747 Cases. Pathol. Res. Pract. 1992, 188, 908–924. [Google Scholar] [CrossRef]
  10. Tipu, H.N.; Ahmed, T.A.; Bashir, M.M. Clinical, histopathological and immunofluorescent findings of IgA nephropathy. Iran. J. Immunol. 2011, 8, 104. [Google Scholar]
  11. Little, M.A.; Dorman, A.; Gill, D.; Walshe, J.J.; Walshe, J.J. Mesangioproliferative glomerulonephritis with IgM deposition: Clinical characteristics and outcome. Ren. Fail. 2000, 22, 445–457. [Google Scholar] [CrossRef] [PubMed]
  12. John, M.; Lam, M.; Latham, B.; Saker, B.; French, M.A. Nephrotic syndrome in a patient with IgA deficiency-associated mesangioproliferative glomerulonephritis. Pathology 2000, 32, 56–58. [Google Scholar] [CrossRef] [PubMed]
  13. Hassler, J.R. IgA nephropathy: A brief review. Semin. Diagn. Pathol. 2020, 37, 143–147. [Google Scholar] [CrossRef] [PubMed]
  14. Woo, K.T.; Chan, C.M.; Lim, C.; Choo, J.; Chin, Y.M.; Teng, E.W.L.; Mok, I.; Kwek, J.L.; Loh, A.H.L.; Choong, H.L.; et al. A Global Evolutionary Trend of the Frequency of Primary Glomerulonephritis over the Past Four Decades. Kidney Dis. 2019, 5, 247–258. [Google Scholar] [CrossRef]
  15. Rajasekaran, A.; Julian, B.A.; Rizk, D.V. IgA Nephropathy: An Interesting Autoimmune Kidney Disease. Am. J. Med. Sci. 2021, 361, 176–194. [Google Scholar] [CrossRef]
  16. Floege, J.; Rauen, T.; Tang, S.C.W. Current treatment of IgA nephropathy. Semin. Immunopathol. 2021, 43, 717–728. [Google Scholar] [CrossRef]
  17. Peng, A.; Gu, Y.; Lin, S.Y. Herbal treatment for renal diseases. Ann. Acad. Med. Singap. 2005, 34, 44–51. [Google Scholar] [CrossRef]
  18. Isnard Bagnis, C.; Deray, G.; Baumelou, A.; Le Quintrec, M.; Vanherweghem, J.L. Herbs and the kidney. Am. J. Kidney Dis. 2004, 44, 1–11. [Google Scholar] [CrossRef]
  19. Schaal, J.P.; Riethmuller, D.; Martin, A.; Lemouel, A.; Quereux, C.; Maillet, R. Conduite à tenir au cours du travail et de l’accouchement. In Encycl Méd Chir; Elsevier: Amsterdam, The Netherlands, 1998; Paris Obstétrique; Volume 5-049-D-27, 35p. [Google Scholar]
  20. Xia, J.; He, L.Q.; Su, X. Interventional mechanisms of herbs or herbal extracts on renal interstitial fibrosis. J. Integr. Med. 2016, 14, 165–173. [Google Scholar] [CrossRef]
  21. Heo, J.C.; Nam, D.Y.; Seo, M.S.; Lee, S.H. Alleviation of atopic dermatitis-related symptoms by Perilla frutescens Britton. Int. J. Mol. Med. 2011, 28, 733–737. [Google Scholar] [CrossRef] [Green Version]
  22. Yu, H.; Qiu, J.F.; Ma, L.J.; Hu, Y.J.; Li, P.; Wan, J.B. Phytochemical and phytopharmacological review of Perilla frutescens L. (Labiatae), a traditional edible-medicinal herb in China. Food Chem. Toxicol. 2017, 108, 375–391. [Google Scholar] [CrossRef]
  23. Ahmed, H.M. Ethnomedicinal, Phytochemical and Pharmacological Investigations of Perilla frutescens (L.) Britt. Molecules 2018, 24, 102. [Google Scholar] [CrossRef] [Green Version]
  24. Hashimoto, M.; Matsuzaki, K.; Maruyama, K.; Sumiyoshi, E.; Hossain, S.; Wakatsuki, H.; Kato, S.; Ohno, M.; Tanabe, Y.; Kuroda, Y.; et al. Perilla frutescens seed oil combined with Anredera cordifolia leaf powder attenuates age-related cognitive decline by reducing serum triglyceride and glucose levels in healthy elderly Japanese individuals: A possible supplement for brain health. Food Funct. 2022, 13, 7226–7239. [Google Scholar] [CrossRef] [PubMed]
  25. Saita, E.; Kishimoto, Y.; Tani, M.; Iizuka, M.; Toyozaki, M.; Sugihara, N.; Kondo, K. Antioxidant activities of Perilla frutescens against low-density lipoprotein oxidation in vitro and in human subjects. J. Oleo. Sci. 2012, 61, 113–120. [Google Scholar] [CrossRef] [Green Version]
  26. Takano, H.; Osakabe, N.; Sanbongi, C.; Yanagisawa, R.; Inoue, K.; Yasuda, A.; Natsume, M.; Baba, S.; Ichiishi, E.; Yoshikawa, T. Extract of Perilla frutescens enriched for rosmarinic acid, a polyphenolic phytochemical, inhibits seasonal allergic rhinoconjunctivitis in humans. Exp. Biol. Med. 2004, 229, 247–254. [Google Scholar] [CrossRef] [PubMed]
  27. Buchwald-Werner, S.; Fujii, H.; Reule, C.; Schoen, C. Perilla extract improves gastrointestinal discomfort in a randomized placebo controlled double blind human pilot study. BMC Complement. Altern. Med. 2014, 14, 173. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Schirrmacher, G.; Skurk, T.; Hauner, H.; Grassmann, J. Effect of Spinacia oleraceae L. and Perilla frutescens L. on antioxidants and lipid peroxidation in an intervention study in healthy individuals. Plant Foods Hum. Nutr. 2010, 65, 71–76. [Google Scholar] [CrossRef]
  29. Marseglia, G.L.; Licari, A.; Ciprandi, G. A polycentric, randomized, double blind, parallel-group, placebo-controlled study on Lertal®, a multicomponent nutraceutical, as add-on treatment in children with allergic rhinoconjunctivitis: Phase I during active treatment. J. Biol. Regul. Homeost. Agents 2019, 33, 617–622. [Google Scholar] [PubMed]
  30. Adam, G.; Robu, S.; Flutur, M.M.; Cioanca, O.; Vasilache, I.A.; Adam, A.M.; Mircea, C.; Nechita, A.; Harabor, V.; Harabor, A.; et al. Applications of Perilla frutescens Extracts in Clinical Practice. Antioxidants 2023, 12, 727. [Google Scholar] [CrossRef] [PubMed]
  31. Makino, T.; Ono, T.; Muso, E.; Honda, G.; Sasayama, S. Suppressive effects of Perilla frutescens on spontaneous IgA nephropathy in ddY mice. Nephron 1999, 83, 40–46. [Google Scholar] [CrossRef]
  32. Makino, T.; Nakamura, T.; Ono, T.; Muso, E.; Honda, G. Suppressive effects of Perilla frutescens on mesangioproliferative glomerulonephritis in rats. Biol. Pharm. Bull. 2001, 24, 172–175. [Google Scholar] [CrossRef] [Green Version]
  33. Makino, T.; Ono, T.; Liu, N.; Nakamura, T.; Muso, E.; Honda, G. Suppressive effects of rosmarinic acid on mesangioproliferative glomerulonephritis in rats. Nephron 2002, 92, 898–904. [Google Scholar] [CrossRef]
  34. Makino, T.; Ono, T.; Matsuyama, K.; Nogaki, F.; Miyawaki, S.; Honda, G.; Muso, E. Suppressive effects of Perilla frutescens on IgA nephropathy in HIGA mice. Nephrol. Dial. Transplant. 2003, 18, 484–490. [Google Scholar] [CrossRef] [Green Version]
  35. Sakurai, K.; Asahi, K.; Kanesaki, Y.; Hayashi, Y.; Asai, J.; Yuza, T.; Watanabe, K.; Katoh, T.; Watanabe, T. Dietary Perilla seed oil supplement increases plasma omega-3 polyunsaturated fatty acids and ameliorates immunoglobulin A nephropathy in high immunoglobulin A strain of ddY mice. Nephron. Exp. Nephrol. 2011, 119, e33–e39. [Google Scholar] [CrossRef] [PubMed]
  36. Thompson, A.; Carroll, K.; Inker, L.A.; Floege, J.; Perkovic, V.; Boyer-Suavet, S.; Major, R.W.; Schimpf, J.I.; Barratt, J.; Cattran, D.C.; et al. Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. Clin. J. Am. Soc. Nephrol. 2019, 14, 469–481. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Berthoux, F.; Mohey, H.; Laurent, B.; Mariat, C.; Afiani, A.; Thibaudin, L. Predicting the risk for dialysis or death in IgA nephropathy. J. Am. Soc. Nephrol. 2011, 22, 752–761. [Google Scholar] [CrossRef] [Green Version]
  38. Chen, D.; Liu, J.; Duan, S.; Chen, P.; Tang, L.; Zhang, L.; Feng, Z.; Cai, G.; Wu, J.; Chen, X. Clinicopathological Features to Predict Progression of IgA Nephropathy with Mild Proteinuria. Kidney Blood Press. Res. 2018, 43, 318–328. [Google Scholar] [CrossRef] [PubMed]
  39. Reich, H.N.; Troyanov, S.; Scholey, J.W.; Cattran, D.C. Remission of proteinuria improves prognosis in IgA nephropathy. J. Am. Soc. Nephrol. 2007, 18, 3177–3183. [Google Scholar] [CrossRef] [Green Version]
  40. Barbour, S.J.; Cattran, D.C.; Espino-Hernandez, G.; Hladunewich, M.A.; Reich, H.N. Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis. Kidney Int. 2015, 88, 1392–1401. [Google Scholar] [CrossRef] [Green Version]
  41. Adrian, E.K., Jr.; Walker, B.E. Incorporation of thymidine-H3 by cells in normal and injured mouse spinal cord. J. Neuropathol. Exp. Neurol. 1962, 21, 597–609. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Zuo, Y.; Lv, Y.; Qian, X.; Wang, S.; Chen, Z.; Jiang, Q.; Cao, C.; Song, Y. Inhibition of HHIP Promoter Methylation Suppresses Human Gastric Cancer Cell Proliferation and Migration. Cell. Physiol. Biochem. 2018, 45, 1840–1850. [Google Scholar] [CrossRef]
  43. Xie, J.; Li, Q.; Ding, X.; Gao, Y. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells. Cell. Physiol. Biochem. 2018, 46, 676–686. [Google Scholar] [CrossRef]
  44. Zattara, E.E.; Özpolat, B.D. Quantifying Cell Proliferation During Regeneration of Aquatic Worms. Methods Mol. Biol. 2021, 2219, 163–180. [Google Scholar] [CrossRef] [PubMed]
  45. Suzuki, H.; Kiryluk, K.; Novak, J.; Moldoveanu, Z.; Herr, A.B.; Renfrow, M.B.; Wyatt, R.J.; Scolari, F.; Mestecky, J.; Gharavi, A.G. The pathophysiology of IgA nephropathy. J. Am. Soc. Nephrol. 2011, 22, 1795–1803. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Tomana, M.; Novak, J.; Julian, B.A.; Matousovic, K.; Konecny, K.; Mestecky, J. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J. Clin. Investig. 1999, 104, 73–81. [Google Scholar] [CrossRef] [Green Version]
  47. Suzuki, H.; Moldoveanu, Z.; Hall, S.; Brown, R.; Vu, H.L.; Novak, L.; Julian, B.A.; Tomana, M.; Wyatt, R.J.; Edberg, J.C. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J. Clin. Investig. 2008, 118, 629–639. [Google Scholar] [CrossRef] [Green Version]
  48. Suzuki, H.; Fan, R.; Zhang, Z.; Brown, R.; Hall, S.; Julian, B.A.; Chatham, W.W.; Suzuki, Y.; Wyatt, R.J.; Moldoveanu, Z. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J. Clin. Investig. 2009, 119, 1668–1677. [Google Scholar] [CrossRef] [Green Version]
  49. Hastings, M.C.; Moldoveanu, Z.; Suzuki, H.; Berthoux, F.; Julian, B.A.; Sanders, J.T.; Renfrow, M.B.; Novak, J.; Wyatt, R.J. Biomarkers in IgA nephropathy: Relationship to pathogenetic hits. Expert Opin. Med Diagn. 2013, 7, 615–627. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  50. Suzuki, H. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. Clin. Exp. Nephrol. 2019, 23, 26–31. [Google Scholar] [CrossRef] [Green Version]
  51. Takasaki, Y.; Deng, J.S.; Tan, E.M. A nuclear antigen associated with cell proliferation and blast transformation. J. Exp. Med. 1981, 154, 1899–1909. [Google Scholar] [CrossRef] [Green Version]
  52. Celis, J.E.; Celis, A. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: Subdivision of S phase. Proc. Natl. Acad. Sci. USA 1985, 82, 3262–3266. [Google Scholar] [CrossRef]
  53. Nakopoulou, L.; Stefanaki, K.; Salpigidis, K.; Boletis, J.; Papadakis, J.; Zeiss, P.M.; Vosnides, G. The value of proliferating cell nuclear antigen (PCNA)/cyclin in the assessment of cell proliferation in glomerulonephritis. Histol. Histopathol. 1997, 12, 655–662. [Google Scholar]
  54. Trimarchi, H.; Haas, M.; Coppo, R. Crescents and IgA Nephropathy: A Delicate Marriage. J. Clin. Med. 2022, 11, 3569. [Google Scholar] [CrossRef]
  55. Maixnerova, D.; Reily, C.; Bian, Q.; Neprasova, M.; Novak, J.; Tesar, V. Markers for the progression of IgA nephropathy. J. Nephrol. 2016, 29, 535–541. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Lee, H.S.; Lee, M.S.; Lee, S.M.; Lee, S.Y.; Lee, E.S.; Lee, E.Y.; Park, S.Y.; Han, J.S.; Kim, S.; Lee, J.S. Histological grading of IgA nephropathy predicting renal outcome: Revisiting H. S. Lee’s glomerular grading system. Nephrol. Dial. Transplant. 2004, 20, 342–348. [Google Scholar] [CrossRef] [Green Version]
  57. Rodrigues, J.C.; Haas, M.; Reich, H.N. IgA Nephropathy. Clin. J. Am. Soc. Nephrol. 2017, 12, 677–686. [Google Scholar] [CrossRef] [Green Version]
  58. Moriyama, T. Clinical and histological features and therapeutic strategies for IgA nephropathy. Clin. Exp. Nephrol. 2019, 23, 1089–1099. [Google Scholar] [CrossRef]
  59. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Network, I.N.; Cattran, D.C.; Coppo, R.; Cook, H.T.; Feehally, J.; Roberts, I.S.; Troyanov, S.; Alpers, C.E.; Amore, A.; et al. The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int. 2009, 76, 534–545. [Google Scholar]
  60. Barbour, S.J.; Coppo, R.; Zhang, H.; Liu, Z.H.; Suzuki, Y.; Matsuzaki, K.; Katafuchi, R.; Er, L.; Espino-Hernandez, G.; Kim, S.J.; et al. Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Intern. Med. 2019, 179, 942–952. [Google Scholar] [CrossRef] [PubMed]
  61. Duan, W.; Shi-Mei, Y.; Zhi-Wei, S.; Jing, X.; De-Gang, Z.; Hong-Bin, W.; Qi, S. Genome-Wide Analysis of the Fatty Acid Desaturase Gene Family Reveals the Key Role of PfFAD3 in α-Linolenic Acid Biosynthesis in Perilla Seeds. Front. Genet. 2021, 12, 735862. [Google Scholar] [CrossRef]
  62. Liput, K.P.; Lepczyński, A.; Ogłuszka, M.; Nawrocka, A.; Poławska, E.; Grzesiak, A.; Ślaska, B.; Pareek, C.S.; Czarnik, U.; Pierzchała, M. Effects of Dietary n-3 and n-6 Polyunsaturated Fatty Acids in Inflammation and Cancerogenesis. Int. J. Mol. Sci. 2021, 22, 6965. [Google Scholar] [CrossRef]
  63. Baggio, B.; Musacchio, E.; Priante, G. Polyunsaturated fatty acids and renal fibrosis: Pathophysiologic link and potential clinical implications. J. Nephrol. 2005, 18, 362–367. [Google Scholar] [PubMed]
  64. Sethi, S.; Fervenza, F.C. Membranoproliferative glomerulonephritis--a new look at an old entity. N. Engl. J. Med. 2012, 366, 1119–1131. [Google Scholar] [CrossRef] [Green Version]
  65. Yang, E.J.; Ku, S.K.; Lee, W.; Lee, S.; Lee, T.; Song, K.S.; Bae, J.S. Barrier protective effects of rosmarinic acid on HMGB1-induced inflammatory responses in vitro and in vivo. J. Cell. Physiol. 2013, 228, 975–982. [Google Scholar] [CrossRef]
  66. Sanbongi, C.; Takano, H.; Osakabe, N.; Sasa, N.; Natsume, M.; Yanagisawa, R.; Inoue, K.i.; Sadakane, K.; Ichinose, T.; Yoshikawa, T. Rosmarinic acid in perilla extract inhibits allergic inflammation induced by mite allergen, in a mouse model. Clin. Exp. Allergy 2004, 34, 971–977. [Google Scholar] [CrossRef]
  67. Kim, J.S.; Lee, H.J.; Lee, M.H.; Kim, J.; Jin, C.; Ryu, J.H. Luteolin inhibits LPS-stimulated inducible nitric oxide synthase expression in BV-2 microglial cells. Planta Med. 2006, 72, 65–68. [Google Scholar] [CrossRef]
  68. Jeong, Y.Y.; Park, H.S.; Choi, J.H.; Kim, S.H.; Min, K.U. Two cases of anaphylaxis caused by perilla seed. J. Allergy Clin. Immunol. 2006, 117, 1505–1506. [Google Scholar] [CrossRef] [Green Version]
  69. Jung, S.; Lee, W.Y.; Yong, S.J.; Shin, K.; Kim, C.; Lee, J.-H.; Jung, Y.R.; Kim, H.; Yu, T.-S.; Kim, S.-H. Occupational asthma caused by inhaling smoke from roasting perilla seeds. Allergy Asthma Respir. Dis. 2013, 1, 90. [Google Scholar] [CrossRef] [Green Version]
  70. Abernathy, V.J.; Roselli, R.J.; Parker, R.E.; Pou, N.A. Effects of Perilla ketone on the in situ sheep lung. J. Appl. Physiol. 1992, 72, 505–514. [Google Scholar] [CrossRef]
  71. Kerr, L.A.; Johnson, B.J.; Burrows, G.E. Intoxication of cattle by Perilla frutescens (purple mint). Vet. Hum. Toxicol. 1986, 28, 412–416. [Google Scholar]
  72. Zhang, H.-x.; Guan, J.; Tian, Y.-h.; Su, G.-y.; Zhao, Y.-q. Acute and sub-chronic 90-day oral toxicity study of Perilla seed oil in rodents and Beagle dogs. Regul. Toxicol. Pharmacol. 2019, 103, 229–236. [Google Scholar] [CrossRef]
  73. Hooijmans, C.R.; Rovers, M.M.; de Vries, R.B.M.; Leenaars, M.; Ritskes-Hoitinga, M.; Langendam, M.W. SYRCLE’s risk of bias tool for animal studies. BMC Med. Res. Methodol. 2014, 14, 43. [Google Scholar] [CrossRef] [Green Version]
Pharmaceuticals 16 00988 g001 550
Figure 1. Flow diagram of search and selection of studies.
Figure 1. Flow diagram of search and selection of studies.
Pharmaceuticals 16 00988 g001
Pharmaceuticals 16 00988 g002 550
Figure 2. Forrest plot for overall effect size of low-dose Perilla frutescens versus placebo on proteinuria [32,33,34,35].
Figure 2. Forrest plot for overall effect size of low-dose Perilla frutescens versus placebo on proteinuria [32,33,34,35].
Pharmaceuticals 16 00988 g002
Pharmaceuticals 16 00988 g003 550
Figure 3. Forrest plot for overall effect size of high-dose Perilla frutescens versus placebo on proteinuria [32,34].
Figure 3. Forrest plot for overall effect size of high-dose Perilla frutescens versus placebo on proteinuria [32,34].
Pharmaceuticals 16 00988 g003
Pharmaceuticals 16 00988 g004 550
Figure 4. Forrest plot for overall effect size of low-dose Perilla frutescens versus placebo on serum levels of immunoglobulin A [31,34,35].
Figure 4. Forrest plot for overall effect size of low-dose Perilla frutescens versus placebo on serum levels of immunoglobulin A [31,34,35].
Pharmaceuticals 16 00988 g004
Pharmaceuticals 16 00988 g005 550
Figure 5. Forrest plot for overall effect size of high-dose Perilla frutescens versus placebo on serum levels of immunoglobulin A [31,34].
Figure 5. Forrest plot for overall effect size of high-dose Perilla frutescens versus placebo on serum levels of immunoglobulin A [31,34].
Pharmaceuticals 16 00988 g005
Pharmaceuticals 16 00988 g006 550
Figure 6. Forrest plot for overall effect size of low-dose Perilla frutescens versus placebo on the positivity for proliferating cell nuclear antigen (PCNA) [32,33].
Figure 6. Forrest plot for overall effect size of low-dose Perilla frutescens versus placebo on the positivity for proliferating cell nuclear antigen (PCNA) [32,33].
Pharmaceuticals 16 00988 g006
Pharmaceuticals 16 00988 g007 550
Figure 7. Forrest plot for overall effect size of low-dose Perilla frutescens versus placebo on the DNA synthesis [31,32].
Figure 7. Forrest plot for overall effect size of low-dose Perilla frutescens versus placebo on the DNA synthesis [31,32].
Pharmaceuticals 16 00988 g007
Pharmaceuticals 16 00988 g008 550
Figure 8. Forrest plot for overall effect size of high-dose Perilla frutescens versus placebo on the DNA synthesis [31,32].
Figure 8. Forrest plot for overall effect size of high-dose Perilla frutescens versus placebo on the DNA synthesis [31,32].
Pharmaceuticals 16 00988 g008
Pharmaceuticals 16 00988 g009 550
Figure 9. Funnel plot for publication bias.
Figure 9. Funnel plot for publication bias.
Pharmaceuticals 16 00988 g009
Table
Table 1. Characteristics of the included studies.
Table 1. Characteristics of the included studies.
AuthorYearNumber of Subjects IncludedAnimal Model/CellsParts UsedExtractTreatment Groups
Makino et al. [31]199946HYGA miceleavesPerilla frutescens var, crispa, LabiataeLD (50 mg/kg/day)
HD (500 mg/kg/day)
Makino et al. [32]200130Wistar ratsleavesPerilla
frutescens Britton var. crispa		LD (100 mg/kg/day)
HD (500 mg/kg/day)
Makino et al. [33]200224Wistar ratsleavesPerilla frutescensRosmarinic
acid (100 mg/kg/day)
Makino et al. [34]200342HIGA miceleavesPerilla
frutescens Britton var. crispa		LD (50 mg/kg/day)
HD (500 mg/kg/day)
Sakurai et al. [35]201116HIGA miceseed oilPerilla frutescensPerilla seed oil (70 g/kg)
Table legend: IgA—immunoglobulin A; HIGA—High-IgA-prone congenic mice; LD—low-dose group; HD—high-dose group.
Table
Table 2. Quality assessment of the included studies using SYRCLE’s risk of bias tool for animal studies.
Table 2. Quality assessment of the included studies using SYRCLE’s risk of bias tool for animal studies.
StudySelection BiasPerformance BiasDetection
Bias		Attrition BiasReporting BiasOther
Was the Allocation Sequence Adequately Generated and Applied?Were the Groups Similar at Baseline or Were They Adjusted for Confounders in the
Analysis?		Was the Allocation Adequately Concealed?Were the Animals Randomly Housed during the Experiment?Were the Caregivers and/or Investigators Blinded from Knowledge of Which Intervention Each Animal Received during the Experiment?Were Animals Selected at Random for Outcome Assessment?Was the Outcome Assessor
Blinded?		Were Incomplete Outcome Data Adequately Addressed?Are Reports of the Study Free of Selective Outcome Reporting?Was the Study Apparently Free of Other Problems that could Result in High Risk of Bias?
Makino et al. [31]UnclearYesUnclearUnclearNoNoUnclearYesYesYes
Makino et al. [32]UnclearYesUnclearUnclearNoNoUnclearYesYesYes
Makino et al. [33]UnclearYesUnclearUnclearNoNoUnclearYesYesYes
Makino et al. [34]UnclearYesUnclearUnclearNoNoUnclearYesYesYes
Sakurai et al. [35]YesYesUnclearUnclearUnclearNoUnclearYesYesYes
Table
Table 3. The results of the random effects model used for meta-analysis.
Table 3. The results of the random effects model used for meta-analysis.
OutcomeGroupsEffect SizeStd. ErrorZSig. (Two-Tailed)Lower Limit 95% CIUpper Limit 95% CI
ProteinuriaLD vs. placebo−0.850.866−1.0400.30−2.450.75
HD vs. placebo−1.910.499−4.081<0.001−2.91−0.91
IgALD vs. placebo−2.363.795−0.9770.32−6.992.28
HD vs. placebo−2.442.085−1.2140.22−6.371.49
PCNALD vs. placebo−2.940.653−4.856<0.001−4.06−1.82
HD vs. placebo−2.860.861−3.320<0.001−4.54−1.17
[3H] thymodineLD vs. placebo−1.600.627−2.682<0.001−2.68−0.52
HD vs. placebo−2.391.731−1.4600.14−5.460.68
Table legend: IgA—immunoglobulin A; PCNA— proliferating cell nuclear antigen; [3H] thymidine incorporation; CI—confidence interval.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Adam, G.; Adam, A.-M.; Robu, S.; Harabor, V.; Harabor, A.; Nechita, A.; Marin, D.B.; Morariu, I.-D.; Cioanca, O.; Vasilache, I.-A.; et al. The Effects of Perilla frutescens Extracts on IgA Nephropathy: A Systematic Review and Meta-Analysis. Pharmaceuticals 2023, 16, 988. https://doi.org/10.3390/ph16070988

AMA Style

Adam G, Adam A-M, Robu S, Harabor V, Harabor A, Nechita A, Marin DB, Morariu I-D, Cioanca O, Vasilache I-A, et al. The Effects of Perilla frutescens Extracts on IgA Nephropathy: A Systematic Review and Meta-Analysis. Pharmaceuticals. 2023; 16(7):988. https://doi.org/10.3390/ph16070988

Chicago/Turabian Style

Adam, Gigi, Ana-Maria Adam, Silvia Robu, Valeriu Harabor, Anamaria Harabor, Aurel Nechita, Denisa Batir Marin, Ionela-Daniela Morariu, Oana Cioanca, Ingrid-Andrada Vasilache, and et al. 2023. "The Effects of Perilla frutescens Extracts on IgA Nephropathy: A Systematic Review and Meta-Analysis" Pharmaceuticals 16, no. 7: 988. https://doi.org/10.3390/ph16070988

APA Style

Adam, G., Adam, A. -M., Robu, S., Harabor, V., Harabor, A., Nechita, A., Marin, D. B., Morariu, I. -D., Cioanca, O., Vasilache, I. -A., & Hancianu, M. (2023). The Effects of Perilla frutescens Extracts on IgA Nephropathy: A Systematic Review and Meta-Analysis. Pharmaceuticals, 16(7), 988. https://doi.org/10.3390/ph16070988

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop